CTOs on the Move

Baxalta

www.baxalta.com

 
Newly combined with Baxalta, Shire is now the leading global biotechnology company focused on serving people affected by rare diseases and highly specialized conditions. These diseases are often misunderstood, under-diagnosed, and potentially life-threatening. Our 22,000 employees come to work every day with a common purpose: to develop and deliver breakthrough therapies that enable people with life-altering conditions to live their lives to the fullest. At Shire, we are dedicated to expanding, building and sustaining leadership across our key therapeutic areas through our extensive portfolio of products, innovative pipeline and collaborative approach to working with diverse partners around the globe. We strive to ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.baxalta.com
  • 1200 Lakeside Dr
    Bannockburn, IL USA 60015
  • Phone: 224.948.2000

Executives

Name Title Contact Details

Similar Companies

Spectrum Athletic Clubs

Spectrum Athletic Clubs is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Family Counselling Centre

Family Counselling Centre is a Sarnia, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AccessHealth

AccessHealth is a Beckley, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bonnie Bell

Bonnie Bell is a Westlake, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Celator Pharmaceuticals

Celator Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is transforming the science of combination therapy and developing products to improve outcomes for patients with cancer. The Company is working to establish a new treatment paradigm in which rationally-designed, fully-integrated combination products replace combination regimens of individual agents. Celator`s proprietary technology platform, CombiPlex®, identifies the most effective synergistic ratio of the component drugs, optimizes the pharmacology of the drug combination prior to human clinical trials, allows simultaneous administration of the components as a single product and maintains the synergistic ratio of the components after administration thereby exposing tumor cells to the right amounts of drug for the right length of time.